

13. International Commission on Radiological Protection (ICRP). Recommendations of the International Commission on Radiological Protection. Publication 26. *Ann ICRP*. 1977;1:21.
14. International Commission on Radiological Protection (ICRP). Recommendations of the International Commission on Radiological Protection. Publication 60. *Ann ICRP*. 1990;21:7–9.
15. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med*. 2005;46:1023–1027.
16. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. *J Nucl Med*. 1999;40:37S–61S.
17. International Commission on Radiological Protection (ICRP). Basic anatomical and physiological data for use in radiological protection: the skeleton. *Ann ICRP*. 1995;21:66.
18. International Commission on Radiological Protection (ICRP). *Report of the Task Group on Reference Man*. Publication 23. Oxford, U.K.: Pergamon Press; 1975.
19. PET Drug Applications—Content and Format for NDAs and ANDAs. Fludeoxyglucose F 18 Injection, Ammonia N 13 Injection, Sodium Fluoride F 18 Injection, Attachment II, Sample Formats; Labeling for Ammonia N 13 Injection, Fludeoxyglucose F 18 Injection and Sodium Fluoride F 18 Injection, Attachment II (CDER 2000). Washington, DC: United States Food and Drug Administration; 2000.
20. International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals, addendum 2 to ICRP publication 53. Publication 80. *Ann ICRP*. 1999;28.
21. Hansen CL, Goldstein RA, Akinboboye OO, et al. Myocardial perfusion and function: single photon emission computed tomography. *J Nucl Cardiol*. 2007;14:e39–e60.
22. Machac J, Bacharach SL, Bateman TM, et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. *J Nucl Cardiol*. 2006;13:e121–e151.
23. Senthamizhchelvan S, Bravo PE, Esaias C, Sgouros G, Bengel FM. Human biodistribution and radiation dosimetry of <sup>82</sup>Rb. *J Nucl Med*. 2010;51:1592–1599.
24. Maddahi J, Bengel F, Huang H, et al. Phase 1 rest-stress study of F-18 labeled BMS747158 myocardial perfusion PET tracer: human safety, dosimetry, biodistribution, and myocardial imaging characteristics [abstract]. *J Nucl Med*. 2009;50:48P.
25. Case JA, Maddahi J, Bengel FM, Bateman T, Dahlbom M, Lazewatsky J. Imaging properties of F-18 labeled myocardial perfusion PET agent, BMS747158: dosage, acquisition time and scanner type [abstract]. *J Nucl Med*. 2009;50:109P.
26. Case JA, Lazewatsky JL, Hsu BL, Maddahi J, Berman DS, Bateman TM. Iterative technique for optimizing injected tracer dosage and acquisition time for F-18 labeled myocardial perfusion tracer flurpiridaz F-18 [abstract]. *J Nucl Cardiol*. 2010;17:726.
27. Maddahi J, Huang S, Schiepers C, et al. Same day rest-stress protocols for PET imaging with the new F-18 labeled BMS747158 myocardial perfusion trace [abstract]. *J Nucl Med*. 2009;50:219P.
28. Hsu B, Lazewatsky JL, Bateman T, et al. Cardiac phantom simulation of dose injection parameters for one-day rest/stress myocardial perfusion (MPI) PET imaging with BMS747158 tracer [abstract]. *J Nucl Med*. 2010;51:89P.
29. Lazewatsky J, Maddahi J, Berman D, et al. Development of a method for the determination of dose ratio and minimum inter-injection interval for a one-day rest-stress protocol with BMS747158 PET myocardial perfusion agent [abstract]. *J Nucl Med*. 2010;51:166P.
30. Maddahi J, Lee M, Czernin J, et al. F-18 labeled BMS747158 PET myocardial perfusion imaging identifies more severe and extensive stress induced myocardial ischemia than Tc-99m Sestamibi SPECT [abstract]. *J Nucl Med*. 2010; 51:365P.

### Errata

In the article “Novel <sup>64</sup>Cu- and <sup>68</sup>Ga-Labeled RGD Conjugates Show Improved PET Imaging of  $\alpha_v\beta_3$  Integrin Expression and Facile Radiosynthesis,” by Dumont et al. (*J Nucl Med*. 2011;52:1276–1284), support by Deutsche Forschungsgemeinschaft SFB 850 Project B7 was inadvertently omitted from the Acknowledgments. The authors regret the error.

In the article “MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy,” by Wessels et al. (*J Nucl Med*. 2008;49:1884–1889), term “C” in Equation 7B was missing. The corrected equation and preceding sentence should read as follows:

Similarly, the exact expression for times less than infinity (for  $D_T = [R_0/\lambda_e]C$ ) is given by

$$\text{BED} = \frac{R_0}{\lambda_e} C \left[ 1 + \frac{2R_0\lambda_e}{[(\mu - \lambda_e)(\alpha/\beta)]} \frac{A - B}{C} \right], \quad (\text{Eq. 7B})$$

$$\text{where } A = \frac{1 - e^{-2\lambda_e T}}{2\lambda_e}; B = \frac{1 - e^{-(\mu + \lambda_e)T}}{\mu + \lambda_e}; \text{ and } C = 1 - e^{-\lambda_e T}$$

The authors regret the error; they and the MIRD Committee wish to thank Drs. Katarina Sjögreen Gleisner of the University of Lund, Sweden, and Peter Roberson of the University of Michigan for bringing this correction to their attention.